From Mutation to Treatment: Understanding IDH Inhibitors

In this informative webinar, we'll explore the role of IDH inhibitors in brain tumor care, including what they are and how they impact diagnosis and treatment decisions. Attendees will learn about the latest advancements in IDH-targeted therapies, including the newly FDA-approved treatment, vorasidenib.

Learning Goals:
• Understand what IDH inhibitors are and how they are diagnosed
• Learn about how IDH inhibitors influence treatment decisions
• Recognize the role of IDH inhibitors in treatment advancements and patient outcomes

Presented by:
John de Groot, MD
Division Chief of Neuro-oncology
UCSF

For more information, resources or support, visit the abta.org, call (800) 886-2282 or email info@abta.org.

Видео From Mutation to Treatment: Understanding IDH Inhibitors канала American Brain Tumor Association